FDA Revokes Pfizer-BioNTech COVID-19 EUA as Comirnaty Holds Full Biologics Approval

The August 27, 2025 revocation of Pfizer-BioNTech's COVID-19 Emergency Use Authorization by the FDA closes a regulatory chapter that reshaped how biologics manufacturers operate under emergency frameworks, and sets a compliance baseline every QA director and regulatory affairs lead should document before the next pandemic-era product cycle begins.

With the EUA formally revoked, Comirnaty (COVID-19 Vaccine, mRNA) continues under full FDA biologics approval, meaning all remaining distributed lots and any future releases must conform entirely to 21 CFR Part 601 licensure requirements rather than the abbreviated EUA lot release pathway. For manufacturing sites still holding EUA-labeled inventory, the revocation letter dated August 27, 2025 triggers an immediate labeling changeover obligation; EUA fact sheets updated as recently as June 25, 2025 are no longer the controlling patient and healthcare provider documents.

The compliance read for plant heads centers on lot disposition. Any inventory released under the EUA framework before revocation must be reconciled against current approved labeling, and distribution records should reflect the transition date with precision. CAPA documentation covering the labeling changeover will be a natural inspection focal point under ICH Q10 pharmaceutical quality system expectations, particularly where EUA and BLA-compliant materials were co-managed within the same facility.

The broader manufacturing lesson embedded in this revocation is procedural: the EUA pathway compressed timelines for lot release, labeling, and post-market commitments in ways that full licensure does not permit. Manufacturers who built pandemic-era SOPs around EUA flexibilities will need to audit those procedures against BLA-standard requirements, including sterility assurance documentation, process validation records, and the full suite of 21 CFR Part 211 current GMP obligations.

The FDA's revocation memorandum, also dated August 27, 2025, provides the regulatory rationale and should be reviewed alongside the granting letters from December 2023 and June 2025 to map the full authorization history for internal compliance files.

The measurable outcome to track is whether Pfizer's post-revocation lot release cadence under BLA requirements maintains the supply continuity established during the EUA period, a benchmark that will inform regulatory strategy for any biologics manufacturer preparing a pandemic-preparedness dossier.

Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov RSS Feed, June 10, 2026.